Zivo Bioscience (ZIVO) 10% owner Strome bought 20,259 shares for $250K at $12.34

Insider transactions reported

Mark E Strome (10% owner at Zivo Bioscience Inc., ZIVO) reported that they bought 20,259 shares for $250K at $12.34 on Oct 13, 2025. After these transactions the filing shows 452,942 shares held indirectly (By entity).

Reporting person

Strome Mark E

Options and other derivatives

Holdings before and after

• Common Stock: 432,683 to 452,942 indirect, By entity
• Common Stock Purchase Warrant: 41,046 to 43,071 indirect, By entity

Footnotes from the filing

1. 1. The reported securities are owned directly by Strome Mezzanine Fund II, LP ( SMF II ), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer.
2. 2. Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the Reporting Persons ) may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the Exchange Act ).
3. 3. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Transaction codes in this filing

Open-market purchase:

Code P marks a purchase in the open market or a private deal. The insider paid for these securities.

FAQ